CY1115413T1 - Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation - Google Patents

Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation

Info

Publication number
CY1115413T1
CY1115413T1 CY20141100402T CY141100402T CY1115413T1 CY 1115413 T1 CY1115413 T1 CY 1115413T1 CY 20141100402 T CY20141100402 T CY 20141100402T CY 141100402 T CY141100402 T CY 141100402T CY 1115413 T1 CY1115413 T1 CY 1115413T1
Authority
CY
Cyprus
Prior art keywords
alpha
fsh
sialylation
recovered
includes alpha
Prior art date
Application number
CY20141100402T
Other languages
Greek (el)
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115413(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of CY1115413T1 publication Critical patent/CY1115413T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20141100402T 2008-04-16 2014-06-06 Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation CY1115413T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
CY1115413T1 true CY1115413T1 (el) 2017-01-04

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100402T CY1115413T1 (el) 2008-04-16 2014-06-06 Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation

Country Status (29)

Country Link
US (6) US8951967B2 (enExample)
EP (7) EP3144318B1 (enExample)
JP (7) JP2011519359A (enExample)
KR (5) KR20170110741A (enExample)
CN (3) CN102066414A (enExample)
AR (1) AR071479A1 (enExample)
AU (5) AU2009237479B2 (enExample)
BR (1) BRPI0910461B8 (enExample)
CA (1) CA2725257A1 (enExample)
CY (1) CY1115413T1 (enExample)
DK (6) DK3045471T3 (enExample)
ES (5) ES2629392T3 (enExample)
FI (4) FI4015527T3 (enExample)
FR (3) FR17C1020I2 (enExample)
HR (5) HRP20250313T1 (enExample)
HU (9) HUE071059T2 (enExample)
IL (2) IL208538A (enExample)
LT (8) LT3045471T (enExample)
MX (3) MX2010011343A (enExample)
NO (4) NO2017025I1 (enExample)
NZ (1) NZ588381A (enExample)
PL (6) PL3144318T3 (enExample)
PT (6) PT3098234T (enExample)
RU (3) RU2682270C2 (enExample)
SA (1) SA109300228B1 (enExample)
SI (6) SI2268666T1 (enExample)
TW (1) TWI488640B (enExample)
WO (1) WO2009127826A1 (enExample)
ZA (1) ZA201007373B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HUE025514T2 (en) 2010-09-29 2016-02-29 Ferring Bv Preparation for use in treating infertility
KR101898302B1 (ko) 2010-10-15 2018-09-13 제이씨알 파마 가부시키가이샤 당사슬의 비환원 말단이 만노오스 잔기인 당 단백질의 제조 방법
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Jcrファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
ES2879838T3 (es) 2015-04-17 2021-11-23 Ferring Bv Composición que comprende FSH para el tratamiento de la esterilidad
CN107709350A (zh) * 2015-06-26 2018-02-16 辉凌公司 纯化和/或病毒灭活的方法
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
ES2989511T3 (es) 2017-09-01 2024-11-26 Ferring Bv Composición para la estimulación ovárica controlada
EP4534145A3 (en) 2018-04-30 2025-07-02 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
EP4504236A1 (en) 2022-04-01 2025-02-12 Ferring B.V. Mixed protocol for treatment of infertility
JP2025516966A (ja) 2022-05-26 2025-05-30 フェリング ベスローテン フェンノートシャップ 男性の不妊症の治療のための組成物及び方法
EP4551244A1 (en) 2022-07-08 2025-05-14 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
TW202504578A (zh) 2023-07-20 2025-02-01 荷蘭商輝凌責任有限公司 緩釋載藥微粒

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
DE69823046T2 (de) 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
WO2000067778A1 (en) 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2002340562B2 (en) * 2001-10-22 2008-10-23 Merck Serono Sa Compositions of FSH with high sialylation degree and their use for the preparation of medicaments
ATE542904T1 (de) 2001-10-29 2012-02-15 Crucell Holland Bv Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
CA2554968C (en) 2004-02-04 2012-03-27 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HUE025514T2 (en) 2010-09-29 2016-02-29 Ferring Bv Preparation for use in treating infertility
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
EP3131571A1 (en) 2014-04-18 2017-02-22 Glycotope GmbH Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
ES2468318T3 (es) 2014-06-16
EP2268666B1 (en) 2014-03-12
LT3045471T (lt) 2017-07-10
EP3144318A1 (en) 2017-03-22
SA109300228B1 (ar) 2014-04-08
EP3045471B1 (en) 2017-03-29
PL3045471T3 (pl) 2017-10-31
RU2537268C2 (ru) 2014-12-27
HUE033830T2 (en) 2018-01-29
LT2808340T (lt) 2016-11-10
EP2722339A1 (en) 2014-04-23
TW200948378A (en) 2009-12-01
HUS2500029I1 (hu) 2025-07-28
FR17C1020I2 (fr) 2020-04-10
KR20190092608A (ko) 2019-08-07
HRP20241187T1 (hr) 2024-12-06
AU2017225020B2 (en) 2019-11-14
US9546204B2 (en) 2017-01-17
EP3144318B1 (en) 2020-09-23
US20150065695A1 (en) 2015-03-05
KR20160056960A (ko) 2016-05-20
SI2268666T1 (sl) 2014-07-31
JP7316905B2 (ja) 2023-07-28
SI3098234T1 (sl) 2024-10-30
AU2014203277B2 (en) 2017-04-06
RU2682270C2 (ru) 2019-03-18
CN105906703A (zh) 2016-08-31
US20110105398A1 (en) 2011-05-05
AU2017204259B2 (en) 2017-08-17
US11952407B2 (en) 2024-04-09
CA2725257A1 (en) 2009-10-22
LTPA2017029I1 (lt) 2017-10-10
MX348622B (es) 2017-06-22
FR25C1003I1 (fr) 2025-02-28
NO2017050I1 (no) 2017-09-28
KR20180095140A (ko) 2018-08-24
HUS1700036I1 (hu) 2017-10-30
SI4015527T1 (sl) 2025-05-30
PL2268666T3 (pl) 2014-08-29
FI3098234T3 (fi) 2024-10-31
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
HUE030652T2 (en) 2017-05-29
HUS2500008I1 (hu) 2025-02-28
JP6762916B2 (ja) 2020-09-30
RU2014141994A (ru) 2016-05-10
PT4015527T (pt) 2025-04-10
FR17C1020I1 (enExample) 2020-04-10
BRPI0910461A8 (pt) 2018-10-16
RU2014141994A3 (enExample) 2018-05-28
PT2268666E (pt) 2014-06-25
RU2745557C3 (ru) 2021-12-10
NO2025032I1 (no) 2025-07-14
HUS1700025I1 (hu) 2017-06-28
HK1199039A1 (en) 2015-06-19
FI4015527T3 (fi) 2025-04-29
LT3098234T (lt) 2024-09-10
PT3144318T (pt) 2020-11-04
ES2629392T3 (es) 2017-08-09
BRPI0910461B8 (pt) 2021-05-25
US9771407B2 (en) 2017-09-26
ES2989729T3 (es) 2024-11-27
AU2017225020A1 (en) 2017-09-28
NO2025006I1 (no) 2025-01-16
RU2745557C1 (ru) 2021-03-29
JP6486310B2 (ja) 2019-03-20
FR25C1025I1 (fr) 2025-09-19
NZ588381A (en) 2012-05-25
AU2014203277A1 (en) 2014-07-24
EP2268666A1 (en) 2011-01-05
JP2011519359A (ja) 2011-07-07
RU2010141908A (ru) 2012-05-27
EP3098234B1 (en) 2024-07-31
BRPI0910461B1 (pt) 2021-02-23
DK3144318T3 (da) 2020-12-07
EP4015527B1 (en) 2025-01-22
EP2808340A1 (en) 2014-12-03
LT4015527T (lt) 2025-04-10
JP2015120696A (ja) 2015-07-02
LTPA2025505I1 (enExample) 2025-02-10
EP4015527A1 (en) 2022-06-22
DK2808340T3 (en) 2016-12-05
HUE068565T2 (hu) 2025-01-28
US20160347811A1 (en) 2016-12-01
EP3098234A1 (en) 2016-11-30
FIC20250003I1 (fi) 2025-01-15
DK2268666T3 (da) 2014-05-12
AU2009237479B2 (en) 2014-05-15
HRP20161520T1 (hr) 2016-12-30
AU2017204258B2 (en) 2017-08-17
KR102108377B1 (ko) 2020-05-08
HRP20250313T1 (hr) 2025-05-09
HK1146284A1 (en) 2011-05-20
KR20110005863A (ko) 2011-01-19
ZA201007373B (en) 2011-06-29
KR20170110741A (ko) 2017-10-11
CN102066414A (zh) 2011-05-18
PT3098234T (pt) 2024-10-21
JP2020040956A (ja) 2020-03-19
AU2017204258A1 (en) 2017-07-20
AU2009237479A1 (en) 2009-10-22
KR101622944B1 (ko) 2016-05-23
JP2017060476A (ja) 2017-03-30
CN105906702A (zh) 2016-08-31
EP3045471A1 (en) 2016-07-20
HUS1700024I1 (hu) 2017-06-28
US20180079794A1 (en) 2018-03-22
PL3144318T3 (pl) 2021-02-08
BRPI0910461A2 (pt) 2018-03-27
IL208538A (en) 2014-03-31
JP2022031652A (ja) 2022-02-22
EP2808340B1 (en) 2016-08-17
US20210332099A1 (en) 2021-10-28
TWI488640B (zh) 2015-06-21
AU2017204259A1 (en) 2017-07-20
US10995128B2 (en) 2021-05-04
NO2017025I1 (no) 2017-06-06
ES3023526T3 (en) 2025-06-02
AU2014203277C1 (en) 2017-07-27
JP2018021037A (ja) 2018-02-08
DK4015527T3 (da) 2025-04-14
SI3045471T1 (sl) 2017-07-31
SI3144318T1 (sl) 2020-12-31
FIC20250025I1 (fi) 2025-07-11
LTPA2017018I1 (lt) 2017-06-26
HUE071059T2 (hu) 2025-07-28
HRP20170958T1 (hr) 2017-09-22
WO2009127826A1 (en) 2009-10-22
IL230571A (en) 2015-11-30
LTPA2025525I1 (enExample) 2025-07-25
PL2808340T3 (pl) 2017-02-28
US20240327487A1 (en) 2024-10-03
MX355457B (es) 2018-04-19
PT3045471T (pt) 2017-06-14
PL3098234T3 (pl) 2025-01-07
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
PT2808340T (pt) 2016-11-21
DK3045471T3 (en) 2017-06-26
JP2024038000A (ja) 2024-03-19
SI2808340T1 (sl) 2016-12-30
AR071479A1 (es) 2010-06-23
IL208538A0 (en) 2010-12-30
DK3098234T3 (da) 2024-10-21
HUE030652T4 (en) 2017-09-28
US8951967B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
CY1115413T1 (el) Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
CY1116622T1 (el) Αντισωματα anti-cd22, τα ανοσοσυζευγματα τους και χρησεις αυτων
PH12015500243B1 (en) Glycoconjugation processes and compositions
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
EA201100268A1 (ru) Вакцина
PH12013502192A1 (en) Antibodies against human angiopoietin 2
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EA201100908A1 (ru) Расширенные растворимые полипептиды рн20 и их использование
MX366935B (es) Peptidos intestinales vasoactivos modificados.
FR2941231B1 (fr) Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
MX2016007063A (es) Peptidos terapeuticos.
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
EA201100868A1 (ru) Противоопухолевые комбинации, содержащие антитела, специфически распознающие cd38, и цитарабин
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
IL176142A (en) Processes for preparing montelukast sodium
EP3676250A4 (en) PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF
SG10201805749QA (en) Substantially animal protein-free recombinant furin and methods for producing same
WO2010014922A3 (en) Protein purification tags and uses thereof
MA32321B1 (fr) Pregn-4-en-21, 17 carbolactones substitués sur le noyau c, et préparations pharmaceutiques contenant ces derniers
MX2009003300A (es) Vectores de rhinovirus recombinantes.
MX2015012905A (es) Formulaciones de factor viii recombinantes.
FR2941232B1 (fr) Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина